The oncogenic activation of human p21ras by a novel mechanism

Area of Science:

• Molecular Biology
• Biochemistry
• Oncology

Background:

• The human H-ras protein plays a crucial role in cellular signaling pathways.
• Aberrant H-ras activity is implicated in various cancers.
• Residue 116 of H-ras has been structurally proposed as a guanine nucleotide binding site.

Purpose of the Study:

• To investigate the functional consequences of amino acid substitutions at residue 116 of the human H-ras protein.
• To determine the effect of these mutations on guanosine triphosphate (GTP) binding and hydrolysis.
• To assess the impact of these alterations on the transforming capacity of H-ras.

Main Methods:

• Site-directed mutagenesis was employed to introduce single amino acid changes at residue 116 in both normal and activated forms of H-ras.
• Guanosine triphosphate (GTP) binding assays were performed.
• GTP hydrolysis assays were conducted.
• Cellular transformation assays were utilized to evaluate oncogenic potential.

Main Results:

• Substitutions at residue 116 significantly reduced the ability of both normal and activated H-ras to bind and hydrolyze guanosine triphosphate (GTP).
• These substitutions did not consistently diminish the transforming capacity of activated H-ras derivatives.
• One specific substitution that severely impaired GTP binding and hydrolysis paradoxically activated the transforming potential of the normal H-ras polypeptide.

Conclusions:

• Residue 116 is critical for the guanine nucleotide binding and hydrolytic functions of H-ras.
• Impairment of GTPase activity at residue 116 does not necessarily abolish the transforming potential of activated H-ras.
• Dysregulation of H-ras at residue 116 can lead to oncogenic transformation, even in the absence of typical activating mutations.